Premium
Preparation and quality control of 211 At‐labelled and 125 I‐labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts
Author(s) -
Larsen Roy H.,
Hoff Per,
Alstad Jorolf,
Bruland Øyvind S.
Publication year - 1994
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2580340811
Subject(s) - biodistribution , osteosarcoma , chemistry , monoclonal antibody , radioimmunotherapy , radiochemistry , antibody , in vivo , microbiology and biotechnology , in vitro , nuclear medicine , pathology , biochemistry , immunology , biology , medicine
Two anti‐osteosarcoma monoclonal antibodies (TP‐3 IgG and TP‐1 F(ab′) 2 ) were labelled with the α‐particle emitting radionuclide 211 At and, for comparison of stability, with 125 I using the N‐succinimidyl‐3‐(trimethylstannyl)benzoate intermediate. The quality of the final preparations was measured with immunoreactivity analyses using intact osteosarcoma cells. Immunoreactivity was well retained with values in the range of 65% to 85% for 211 At‐labelled and 125 I‐labelled TP‐3 IgG and approximately 60% for both 211 At‐labelled and 125 I‐labelled TP‐1 F(ab) 2 . Tumour uptake and retention as well as normal tissue distribution in mice with osteosarcoma xenografts were measured. The uptake of the two radionuclides in tumour was similar, while there was a slight general increase in normal tissue activity at later points for the 211 At‐labelled MoAbs compared to the 125 I‐labelled MoAbs, probably caused by a minor release of free 211 At from the MoAb preparations. The stable retention in tumor tissue demonstrated in this study indicates that 211 At‐labelled MoAbs may have potential in the treatment of tumours that allow a rapid uptake.